药明康德
(603259)
| 流通市值：3512.31亿 | | | 总市值：4309.87亿 |
| 流通股本：24.73亿 | | | 总股本：30.35亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 45,537,430,834.54 | 28,897,478,718.36 | 12,435,776,568.29 | 45,456,165,774.18 |
| 营业收入 | 45,537,430,834.54 | 28,897,478,718.36 | 12,435,776,568.29 | 45,456,165,774.18 |
| 二、营业总成本 | 25,611,145,432.57 | 16,254,491,694.29 | 7,433,446,073.33 | 29,148,154,763.35 |
| 营业成本 | 20,856,727,941.26 | 13,318,999,549.58 | 6,167,822,778.36 | 23,801,434,557.94 |
| 税金及附加 | 367,413,832.29 | 235,901,771.31 | 92,179,839.85 | 361,477,739.23 |
| 销售费用 | 624,349,110.04 | 390,792,852.2 | 182,056,633.56 | 806,867,421.28 |
| 管理费用 | 2,510,461,907.82 | 1,490,526,007.94 | 709,748,017.05 | 2,660,731,035.82 |
| 研发费用 | 923,403,112.82 | 605,013,674.54 | 266,956,709.12 | 1,119,452,992.76 |
| 财务费用 | 328,789,528.34 | 213,257,838.72 | 14,682,095.39 | 398,191,016.32 |
| 其中:利息费用 | 163,374,079.51 | 89,688,363.32 | 30,952,924.14 | 268,379,352.78 |
| 其中:利息收入 | 783,191,727.1 | 527,425,948.34 | 274,983,078.16 | 938,021,864.11 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 164,293,979.4 | 684,234,468.06 | 459,260,746.85 | -137,097,911.32 |
| 加:投资收益 | 3,970,957,826.94 | 227,724,271.36 | 164,837,080.44 | 8,588,017,064.9 |
| 资产处置收益 | -7,295,975.28 | -914,869.48 | 2,162,406.4 | -58,067,020.13 |
| 资产减值损失(新) | -89,140,825.88 | -68,368,895.87 | -41,177,323.17 | -541,555,966.37 |
| 信用减值损失(新) | -138,985,937.74 | -93,965,171.38 | -63,930,643.66 | -527,962,030.16 |
| 其他收益 | 244,351,408.07 | 138,631,166.86 | 91,453,793.37 | 298,738,643.85 |
| 四、营业利润 | 24,070,465,877.48 | 13,530,327,993.62 | 5,614,936,555.19 | 23,930,083,791.6 |
| 加:营业外收入 | 14,311,963.27 | 10,728,224.09 | 6,577,970.54 | 31,398,314.78 |
| 减:营业外支出 | 35,287,410.03 | 23,497,152.44 | 14,234,269.52 | 55,330,859.93 |
| 五、利润总额 | 24,049,490,430.72 | 13,517,559,065.27 | 5,607,280,256.21 | 23,906,151,246.45 |
| 减:所得税费用 | 4,544,067,614.64 | 2,391,225,121.37 | 936,766,274.88 | 4,573,085,354.19 |
| 六、净利润 | 19,505,422,816.08 | 11,126,333,943.9 | 4,670,513,981.33 | 19,333,065,892.26 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 19,451,742,836.68 | 11,083,865,878.49 | 4,652,597,022.26 | 17,977,669,327.23 |
| 终止经营净利润 | 53,679,979.4 | 42,468,065.41 | 17,916,959.07 | 1,355,396,565.03 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 19,398,304,296.86 | 11,080,173,661.42 | 4,651,517,987.76 | 19,150,582,400.69 |
| 少数股东损益 | 107,118,519.22 | 46,160,282.48 | 18,995,993.57 | 182,483,491.57 |
| 扣除非经常损益后的净利润 | 16,476,713,443.03 | 10,572,177,317.83 | 4,275,624,429.82 | 13,240,556,954.42 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 6.66 | 3.8 | 1.59 | 6.7 |
| (二)稀释每股收益 | 6.55 | 3.76 | 1.58 | 6.61 |
| 八、其他综合收益 | -936,050,415.72 | -514,298,277.29 | -273,737,529.63 | -449,776,946.3 |
| 归属于母公司股东的其他综合收益 | -931,312,827.47 | -512,206,140.97 | -268,621,140.23 | -447,995,390.63 |
| 九、综合收益总额 | 18,569,372,400.36 | 10,612,035,666.61 | 4,396,776,451.7 | 18,883,288,945.96 |
| 归属于母公司股东的综合收益总额 | 18,466,991,469.39 | 10,567,967,520.45 | 4,382,896,847.53 | 18,702,587,010.06 |
| 归属于少数股东的综合收益总额 | 102,380,930.97 | 44,068,146.16 | 13,879,604.17 | 180,701,935.9 |
| 公告日期 | 2026-10-27 | 2026-08-04 | 2026-04-28 | 2026-03-24 |
| 审计意见(境内) | | | | 标准无保留意见 |